A Phase 3 interventional study of AVP-786 and Placebo in Agitation in Patients With Dementia of the Alzheimer's Type, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 95 sites in 11 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Eligible participants for this study had a diagnosis of probable Alzheimer's disease (AD) and had clinically significant, moderate/severe agitation secondary to AD.
This was a multicenter, randomized, double-blind, placebo-controlled study, consisting of 12 weeks of treatment. Screening occurred within 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants were randomized into the study.
184 participants were enrolled into the study.
Study medication was administered orally twice daily from Day 1 through Day 85.
231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.
This study's enrollment of 184 is above the median of 100 across 188 interventional studies indexed under Psychomotor Agitation.
Browse Psychomotor Agitation studies →Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Compared within Psychomotor Agitation, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786 matching placebo capsules, twice a day, for 11 weeks in Period B.
Drug: Placebo
Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786-18 (d6-DM 18 milligrams (mg)/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B.
Drug: AVP-786
Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B.
Drug: AVP-786
Drug pages: Deudextromethorphan · Quinidine
oral capsules
oral capsules
Change From the End of Period A (Week 1) to Week 10 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score
The CMAI is used to assess the frequency of manifestations of agitated behaviors in elderly persons. It consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. These distinct agitation syndromes include aggressive behavior, physically nonaggressive behavior, and verbally agitated behavior. Each of the 29 items is rated on a 7-point scale of frequency (1 = never, 2 = less than once a week but still occurring, 3 = once or twice a week, 4 = several times a week, 5 = once or twice a day, 6 = several times a day, 7 = several times an hour). The ratings are based on the 2 weeks preceding assessment of the CMAI. Higher scores indicate higher frequency of agitated behaviours while lower scores indicate lower frequency of agitated behaviours.
Time frame: Week 1 to Week 10
Number of Participants With Treatment Emergent Adverse Events (TEAE) and Serious TEAE
An adverse event (AE) is any untoward medical occurrence or unintended change (eg, physical, psychological, or behavioral), including inter-current illness, that does not necessarily have a causal relationship with the study treatment. A serious adverse event (SAE) is any AE occurring at any dose that results in death, life-threatening experience, persistent or significant disability/incapacity, in-patient hospitalization or prolongation of hospitalization or congenital anomaly/birth defect. TEAEs are all AEs (including serious and non-serious) which started after start of double-blind study drug treatment; or if the event was continuous from baseline and was worsening, serious, study drug related, or resulted in death, discontinuation, interruption or reduction of study therapy.
Time frame: From randomization (Week 2) up to 30 days after last dose of study drug (Up to Week 16)
Change From the End of Period A (Week 1) to Week 10 in the Clinical Global Impression of Severity of Illness (CGIS) Score, as Related to Agitation
The CGIS is an observer-rated scale that measures illness severity. The CGIS-Agitation is a 7-point (1-7) scale (1 = normal, not at all ill; 7 = among the most extremely ill patients) and assesses severity of agitation in this study. Higher scores indicate severe agitation while the lower scores indicate little or no agitation.
Time frame: Week 1 to Week 10
Participants took part in the study at clinical sites in the North America and Europe from 13 July 2020 to 27 June 2024.
| Milestone | All Enrolled | Placebo | AVP-786-18 | AVP-786-42.63 |
|---|---|---|---|---|
| Started | 184 | 0 | 0 | 0 |
| Completed | 173 | 0 | 0 | 0 |
| Not completed | 11 | 0 | 0 | 0 |
| Withdrew: Other | 11 | 0 | 0 | 0 |
| Milestone | All Enrolled | Placebo | AVP-786-18 | AVP-786-42.63 |
|---|---|---|---|---|
| Started | 0 | 56 | 60 | 57 |
| Safety population | 0 | 56 | 60 | 57 |
| Completed | 0 | 44 | 48 | 48 |
| Not completed | 0 | 12 | 12 | 9 |
| Withdrew: Adverse event | 0 | 3 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 0 |
| Withdrew: Study subject withdrawal by parent or guardian | 0 | 2 | 2 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 5 | 3 |
| Withdrew: Withdrawal by subject | 0 | 3 | 2 | 1 |
| Withdrew: Reason not specified | 0 | 1 | 0 | 2 |
The CMAI is used to assess the frequency of manifestations of agitated behaviors in elderly persons. It consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. These distinct agitation syndromes include aggressive behavior, physically nonaggressive behavior, and verbally agitated behavior. Each of the 29 items is rated on a 7-point scale of frequency (1 = never, 2 = less than once a week but still occurring, 3 = once or twice a week, 4 = several times a week, 5 = once or twice a day, 6 = several times a day, 7 = several times an hour). The ratings are based on the 2 weeks preceding assessment of the CMAI. Higher scores indicate higher frequency of agitated behaviours while lower scores indicate lower frequency of agitated behaviours.
No measurements were reported for this outcome.
An adverse event (AE) is any untoward medical occurrence or unintended change (eg, physical, psychological, or behavioral), including inter-current illness, that does not necessarily have a causal relationship with the study treatment. A serious adverse event (SAE) is any AE occurring at any dose that results in death, life-threatening experience, persistent or significant disability/incapacity, in-patient hospitalization or prolongation of hospitalization or congenital anomaly/birth defect. TEAEs are all AEs (including serious and non-serious) which started after start of double-blind study drug treatment; or if the event was continuous from baseline and was worsening, serious, study drug related, or resulted in death, discontinuation, interruption or reduction of study therapy.
| Participants | Placebo | AVP-786-18 | AVP-786-42.63 |
|---|---|---|---|
| TEAEs | 20 | 15 | 17 |
| Serious TEAEs | 1 | 3 | 2 |
The CGIS is an observer-rated scale that measures illness severity. The CGIS-Agitation is a 7-point (1-7) scale (1 = normal, not at all ill; 7 = among the most extremely ill patients) and assesses severity of agitation in this study. Higher scores indicate severe agitation while the lower scores indicate little or no agitation.
No measurements were reported for this outcome.
Collected over From randomization (Week 2) up to 30 days after last dose of study drug (Up to Week 16). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/56 (0%) | 1/56 (1.8%) | 20/56 (35.7%) |
| AVP-786-18 | 1/60 (1.7%) | 3/60 (5%) | 14/60 (23.3%) |
| AVP-786-42.63 | 0/57 (0%) | 2/57 (3.5%) | 17/57 (29.8%) |
| Event | Placebo | AVP-786-18 | AVP-786-42.63 |
|---|---|---|---|
| Cerebrovascular accidentNervous system disorders | 0/56 | 2/60 | 0/57 |
| VomitingGastrointestinal disorders | 1/56 | 0/60 | 0/57 |
| Failure to thriveMetabolism and nutrition disorders | 1/56 | 0/60 | 0/57 |
| SyncopeNervous system disorders | 1/56 | 0/60 | 0/57 |
| AgitationPsychiatric disorders | 0/56 | 0/60 | 1/57 |
| Mental status changesPsychiatric disorders | 0/56 | 0/60 | 1/57 |
| Renal impairmentRenal and urinary disorders | 0/56 | 0/60 | 1/57 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/56 | 0/60 | 1/57 |
| Cardio-respiratory arrestCardiac disorders | 0/56 | 1/60 | 0/57 |
| Small intestinal obstructionGastrointestinal disorders | 0/56 | 1/60 | 0/57 |
| Event | Placebo | AVP-786-18 | AVP-786-42.63 |
|---|---|---|---|
| DizzinessNervous system disorders | 4/56 | 0/60 | 3/57 |
| Urinary tract infectionInfections and infestations | 2/56 | 4/60 | 0/57 |
| DiarrhoeaGastrointestinal disorders | 3/56 | 0/60 | 1/57 |
| FallInjury, poisoning and procedural complications | 2/56 | 3/60 | 2/57 |
| Atrial fibrillationCardiac disorders | 2/56 | 1/60 | 0/57 |
| HypotensionVascular disorders | 2/56 | 0/60 | 0/57 |
| Skin lacerationInjury, poisoning and procedural complications | 0/56 | 1/60 | 2/57 |
| Atrial flutterCardiac disorders | 1/56 | 0/60 | 0/57 |
| Atrioventricular blockCardiac disorders | 1/56 | 0/60 | 0/57 |
| Abdominal discomfortGastrointestinal disorders | 1/56 | 1/60 | 0/57 |
Randomized population included all participants who were randomized in the double-blind period B of the study.
| Age, Continuous(years) | Placebo | AVP-786-18 | AVP-786-42.63 | Total |
|---|---|---|---|---|
| Mean | 76.5 ± 7.52 | 73.9 ± 7.85 | 74.8 ± 6.47 | 75.0 ± 7.35 |
| Sex: Female, Male(Participants) | Placebo | AVP-786-18 | AVP-786-42.63 | Total |
|---|---|---|---|---|
| Female | 36 | 42 | 33 | 111 |
| Male | 20 | 18 | 24 | 62 |
| Race (NIH/OMB)(Participants) | Placebo | AVP-786-18 | AVP-786-42.63 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 5 | 5 | 4 | 14 |
| White | 50 | 55 | 53 | 158 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | AVP-786-18 | AVP-786-42.63 | Total |
|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 32 | 39 | 36 | 107 |
| Ethnicity — Not Hispanic or Latino | 22 | 19 | 20 | 61 |
| Ethnicity — Other | 2 | 2 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Jul 2020 to primary completion in Jun 2024, 47 months.
Results were first posted in May 2025, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Deudextromethorphan · Quinidine
Otsuka Pharmaceutical Development & Commercialization, Inc. →